仟源医药(300254) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥228,896,813.46, a decrease of 11.84% compared to the same period last year[5] - The net profit attributable to shareholders was -¥2,546,073.37, representing a decline of 100.65% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥5,020,360.17, down 43.26% from the previous year[5] - Total operating revenue for Q3 2022 was CNY 633.85 million, a decrease of 11.7% compared to CNY 717.45 million in Q3 2021[23] - The net profit for Q3 2022 was a loss of CNY 2.87 million, compared to a profit of CNY 6.64 million in Q3 2021[24] - The company reported a loss attributable to shareholders of CNY 25.37 million in Q3 2022, compared to a loss of CNY 5.39 million in the previous year[24] - The company reported a total comprehensive loss of CNY 2.87 million for Q3 2022, compared to a comprehensive income of CNY 6.64 million in the same quarter last year[24] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,648,939,537.32, an increase of 8.00% compared to the end of the previous year[5] - Total assets increased to CNY 1.65 billion in Q3 2022, up from CNY 1.53 billion in Q3 2021, reflecting a growth of 8.0%[22] - Total liabilities rose to CNY 848.14 million in Q3 2022, compared to CNY 782.23 million in Q3 2021, marking an increase of 8.4%[22] - The company's total current assets increased to ¥523,907,396.16 from ¥375,891,284.85 at the beginning of the year, representing a growth of approximately 39.3%[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 17,562[12] - The top shareholder, Weng Zhangguo, holds 15,772,409 shares, representing 6.53% of total shares[12] - Zhao Qun, the second-largest shareholder, holds 13,401,892 shares, which is 5.55% of total shares, with 10,051,419 shares under lock-up[12] - The total number of unrestricted shares held by the top ten shareholders includes 15,772,409 shares from Weng Zhangguo and 10,000,000 shares from Shanghai Tongyi Investment Management[12] - The company has not disclosed any relationships or concerted actions among the top ten unrestricted shareholders[12] Cash Flow - The cash flow from operating activities for the year-to-date was ¥61,939,568.65, a decrease of 19.54%[5] - The cash inflow from operating activities for the current period was ¥689,602,195.84, a decrease of 14.3% compared to ¥804,665,843.06 in the previous period[25] - The net cash flow from operating activities was ¥61,939,568.65, down 19.6% from ¥76,981,749.49 in the previous period[25] - The cash inflow from financing activities was ¥327,949,994.52, significantly higher than ¥62,880,000.00 in the previous period[26] - The net cash flow from financing activities was ¥133,646,525.75, improving from -¥108,492,628.30 in the previous period[26] Investments and Expenses - Research and development expenses for Q3 2022 were CNY 36.54 million, a decrease of 11.8% from CNY 41.28 million in Q3 2021[23] - The company terminated the project for the production line upgrade at Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd., reallocating the remaining fundraising of ¥6,560.53 million to supplement working capital permanently[17][18] - Long-term equity investments slightly decreased to ¥89,157,335.35 from ¥90,923,391.56, a reduction of about 1.9%[20] - The company's fixed assets decreased to ¥293,108,187.91 from ¥300,260,615.40, showing a decline of approximately 2.4%[20] - The company's inventory increased slightly to ¥109,723,545.83 from ¥108,384,753.42, indicating a growth of about 1.2%[20]